Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Cash and Equivalents of $5.88 million for fiscal year 2025.
ADIAL PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.88M | +56.8% |
| 2024 | $3.75M | +32.7% |
| 2023 | $2.83M | -29.4% |
| 2022 | $4.00M | -34.0% |
| 2021 | $6.06M | +37.7% |
| 2020 | $4.40M | -35.1% |
| 2019 | $6.78M | +75.2% |
| 2018 | $3.87M | +21102.6% |
| 2017 | $18.2K | -79.3% |
| 2016 | $88.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.61M | -11.5% | -22.1% |
| June 30, 2025 | $5.91M | +79.9% | +150.0% |
| March 31, 2025 | $2.37M | -52.9% | -36.9% |
| December 31, 2024 | $3.75M | +32.7% | -27.9% |
| September 30, 2024 | $5.20M | +1547.6% | +58.3% |
| June 30, 2024 | $3.29M | +169.9% | -34.6% |
| March 31, 2024 | $5.03M | +117.3% | +77.7% |
| December 31, 2023 | $2.83M | -29.4% | +795.0% |
- ADIAL PHARMACEUTICALS, INC. showed an increase of +56.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, ADIAL PHARMACEUTICALS, INC.’s cash and equivalents has grown by 6583.7% (from $88.0 thousand to $5.88 million).
- The most recent figure is from ADIAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: